The Effect of the COVID-19 Pandemic on HbA1c Testing: Prioritization of High-Risk Cases and Impact of Social Deprivation.

COVID-19 Diabetes mellitus Glycated haemoglobin HbA1c Index of multiple deprivation Monitoring Pandemic Recovery

Journal

Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 25 11 2022
accepted: 07 02 2023
medline: 23 2 2023
pubmed: 23 2 2023
entrez: 22 2 2023
Statut: ppublish

Résumé

Studies show that the COVID-19 pandemic disproportionately affected people with diabetes and those from disadvantaged backgrounds. During the first 6 months of the UK lockdown, > 6.6 M glycated haemoglobin (HbA1c) tests were missed. We now report variability in the recovery of HbA1c testing, and its association with diabetes control and demographic characteristics. In a service evaluation, we examined HbA1c testing across ten UK sites (representing 9.9% of England's population) from January 2019 to December 2021. We compared monthly requests from April 2020 to those in the equivalent 2019 months. We examined effects of (i) HbA1c level, (ii) between-practice variability, and (iii) practice demographics. In April 2020, monthly requests dropped to 7.9-18.1% of 2019 volumes. By July 2020, testing had recovered to 61.7-86.9% of 2019 levels. During April-June 2020, we observed a 5.1-fold variation in the reduction of HbA1c testing between general practices (12.4-63.8% of 2019 levels). There was evidence of limited prioritization of testing for patients with HbA1c > 86 mmol/mol during April-June 2020 (4.6% of total tests vs. 2.6% during 2019). Testing in areas with the highest social disadvantage was lower during the first lockdown (April-June 2020; trend test p < 0.001) and two subsequent periods (July-September and October-December 2020; both p < 0.001). By February 2021, testing in the highest deprivation group had a cumulative fall in testing of 34.9% of 2019 levels versus 24.6% in those in the lowest group. Our findings highlight that the pandemic response had a major impact on diabetes monitoring and screening. Despite limited test prioritization in the > 86 mmol/mol group, this failed to acknowledge that those in the 59-86 mmol/mol group require consistent monitoring to achieve the best outcomes. Our findings provide additional evidence that those from poorer backgrounds were disproportionately disadvantaged. Healthcare services should redress this health inequality.

Identifiants

pubmed: 36814045
doi: 10.1007/s13300-023-01380-x
pii: 10.1007/s13300-023-01380-x
pmc: PMC9946287
doi:

Types de publication

Journal Article

Langues

eng

Pagination

691-707

Informations de copyright

© 2023. The Author(s).

Références

Diabetes Ther. 2022 May;13(5):1007-1021
pubmed: 35325361
Lancet Public Health. 2020 Oct;5(10):e543-e550
pubmed: 32979305
BMJ Qual Saf. 2022 Jul;31(7):503-514
pubmed: 34642228
Exp Clin Endocrinol Diabetes. 2017 Oct;125(9):625-633
pubmed: 28407667
BMJ. 2000 Aug 12;321(7258):405-12
pubmed: 10938048
J Clin Pathol. 2023 Mar;76(3):177-184
pubmed: 34645702
Int J Public Health. 2021 May 07;66:635508
pubmed: 34744588
Eur J Clin Invest. 2022 Jun;52(6):e13771
pubmed: 35313009
J Diabetes Res. 2022 May 16;2022:7093707
pubmed: 35615258
Diabetes Care. 2014 Oct;37(10):2731-7
pubmed: 25249670
Eur J Gen Pract. 2020 Dec;26(1):129-133
pubmed: 32985278
N Engl J Med. 2005 Dec 22;353(25):2643-53
pubmed: 16371630
J Epidemiol Community Health. 2010 Nov;64(11):1022-4
pubmed: 20675702
Ann Fam Med. 2020 Jul;18(4):349-354
pubmed: 32661037
Lancet Diabetes Endocrinol. 2022 Aug;10(8):561-570
pubmed: 35636440
BMJ. 2020 Oct 5;371:m3793
pubmed: 33020049
Popul Health Manag. 2021 Feb;24(1):8-9
pubmed: 32603249
Diabetes Care. 2021 Feb;44(2):526-532
pubmed: 33268335
Fam Pract. 2020 Nov 28;37(6):845-853
pubmed: 32820328
Clin Chem Lab Med. 2018 Dec 19;57(2):296-304
pubmed: 30281512
Clin Chem. 2012 May;58(5):906-15
pubmed: 22344287
Soc Sci Med. 2008 Mar;66(5):1034-45
pubmed: 18180089
Int J Qual Health Care. 2022 Sep 16;34(3):
pubmed: 36062971
Diabet Med. 2003 Nov;20(11):921-9
pubmed: 14632718
Diabetes Care. 2020 Nov 2;:
pubmed: 33139407
Prim Care Diabetes. 2022 Apr;16(2):257-263
pubmed: 35033477
Diabetologia. 2018 Apr;61(4):959-967
pubmed: 29264632
Br J Gen Pract. 2013 Apr;63(609):e256-66
pubmed: 23540482
Public Health. 2012 Sep;126 Suppl 1:S4-S10
pubmed: 22784581
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):965-967
pubmed: 32604016
Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-833
pubmed: 32798471
Diabetes Ther. 2021 Aug;12(8):2207-2221
pubmed: 34241812
BMJ. 2021 Sep 17;374:n2244
pubmed: 34535466
BMJ. 2021 Sep 3;374:n2174
pubmed: 34479864

Auteurs

David Holland (D)

The Benchmarking Partnership, Alsager, Cheshire, UK.

Adrian H Heald (AH)

Department of Diabetes and Endocrinology, Salford Royal Hospital, The Northern Care Alliance NHS Foundation Trust, Salford, UK.
The School of Medicine and Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, UK.

Fahmy F W Hanna (FFW)

Department of Diabetes and Endocrinology, University Hospitals of North Midlands NHS Trust, Stoke-On-Trent, Staffordshire, UK.
Centre for Health & Development, Staffordshire University, Staffordshire, UK.

Mike Stedman (M)

Res Consortium, Andover, UK.

Pensée Wu (P)

Department of Obstetrics & Gynaecology, University Hospitals of North Midlands NHS Trust, Stoke-On-Trent, Staffordshire, UK.
School of Medicine, Keele University, Keele, Staffordshire, ST5 5BG, UK.

Julius Sim (J)

School of Medicine, Keele University, Keele, Staffordshire, ST5 5BG, UK.

Christopher J Duff (CJ)

School of Medicine, Keele University, Keele, Staffordshire, ST5 5BG, UK.
Department of Clinical Biochemistry, North Midlands and Cheshire Pathology Services, University Hospitals of North Midlands NHS Trust, Stoke-On-Trent, Staffordshire, UK.

Helen Duce (H)

Department of Clinical Biochemistry, North Midlands and Cheshire Pathology Services, University Hospitals of North Midlands NHS Trust, Stoke-On-Trent, Staffordshire, UK.

Lewis Green (L)

Department of Clinical Biochemistry, St. Helens & Knowsley Teaching Hospitals NHS Trust, Whiston Hospital, Prescot, UK.

Jonathan Scargill (J)

Department of Clinical Biochemistry, The Royal Oldham Hospital, The Northern Care Alliance NHS Foundation Trust, Manchester, UK.

Jonathon D Howe (JD)

Department of Clinical Biochemistry, Salford Royal Hospital, The Northern Care Alliance NHS Foundation Trust, Manchester, UK.

Sarah Robinson (S)

Department of Clinical Biochemistry, North Midlands and Cheshire Pathology Services, University Hospitals of North Midlands NHS Trust, Stoke-On-Trent, Staffordshire, UK.

Ian Halsall (I)

Department of Clinical Biochemistry, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK.

Neil Gaskell (N)

Department of Pathology, Warrington & Halton Teaching Hospitals NHS Foundation Trust, Warrington, UK.

Andrew Davison (A)

Department of Clinical Biochemistry & Metabolic Medicine, Liverpool Clinical Laboratories, Liverpool University Hospital NHS Foundation Trust, Liverpool, UK.

Mark Simms (M)

Department of Clinical Biochemistry, Wirral University Teaching Hospital NHS Foundation Trust, Birkenhead, Wirral, UK.

Angela Denny (A)

Department of Clinical Biochemistry, Wirral University Teaching Hospital NHS Foundation Trust, Birkenhead, Wirral, UK.

Martin Langan (M)

Pathology Directorate, Countess of Chester Hospital NHS Foundation Trust, Chester, UK.

Anthony A Fryer (AA)

School of Medicine, Keele University, Keele, Staffordshire, ST5 5BG, UK. a.a.fryer@keele.ac.uk.

Classifications MeSH